跳至主要内容
临床试验/ISRCTN87077451
ISRCTN87077451已完成未知

Short term intraocular pressure trends in high risk patients following intravitreal Ranibizumab (Lucentis) injections for wet age related macular degeneration - is there a role for systemic Acetazolamide (Diamox) in those with glaucoma?

York Teaching Hospital NHS Foundation Trust (UK)0 个研究点目标入组 24 人开始时间: 2012年4月26日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patients with neovascular (wet) AMD requiring Lucentis injections
  • 2. Glaucoma
  • 3. Glaucoma suspect
  • 4. Written informed consent
  • 5. Baseline pre-injection IOP of less than 30mmHg

排除标准

  • 1. Baseline pre-injection IOP of 30 mmHg or higher
  • 2. Unable to give written informed consent
  • 3. Known allergy to sulphur/sulphonamide containing drugs or acetazolamide
  • 4. 18 years or younger
  • 5. Marked kidney or liver disease/dysfunction
  • 6. Supra-renal gland failure
  • 7. Hyperchloremic acidosis
  • 8. Hepatic cirrhosis
  • 9. Pregnancy / [Pre]-menopausal
  • 10. Concomitant use of other oral carbonic anhydrase inhibitors

研究者

发起方
York Teaching Hospital NHS Foundation Trust (UK)

相似试验

Does Diamox have a significant effect on intraocular... | 临床试验